奥沙利铂联合卡培他滨治疗体力状况削弱的晚期胃癌临床观察  

Oxaliplatin plus capecitabine for patients with impaired performance status and advanced gastric cancer

作　　者：苏安[1] 吕霞[1] 王馨[1] 肖莉[1] 张晓东[1] 

机构地区：[1]厦门大学附属中山医院肿瘤科,福建厦门361004

出　　处：《肿瘤防治杂志》2005年第20期1579-1580,共2页China Journal of Cancer Prevention and Treatment

摘　　要：为了评估奥沙利铂联合卡培他滨治疗体力状况削弱的(KPS≤70)晚期胃癌的毒性和疗效,应用奥沙利铂联合卡培他滨治疗21例晚期胃癌患者.奥沙利铂100 mg/m2,静脉滴入,持续3 h,d1;卡培他滨1 650 mg/(m2·d),分2次口服,d1～d14;21 d为1个周期.患者每2个周期行CT检查以评估疗效,并监控其毒性.结果:所有患者均可评估毒性,21例中有20例可评估疗效.PR 6例(30%), SD 8例(40%),PD 6例(30%),有效率为30.0%.中位进展时间4.5个月,中位生存时间8.3 个月.初步研究结果提示:奥沙利铂联合卡培他滨治疗体力状况削弱(KPS≤70)的晚期胃癌有效,且有良好的耐受性.The objective of this study was to evaluate the toxicity and effect of capecitabine combined with oxaliplatin for patients with impaired performance status （KPS≤70） and advanced gastric cancer. Twenty-one patients with measurable adenocarcinoma of stomach were eligible for the study. There patients received oxaliplatin 100 mg/ m^2 ,3-hour intravenous infusion, d1： capecitabine was administered orally twice a day continuously for 14 days in dose 1 650 mg （m^2·d）, repeated every three weeks. Results： All the 21 patients were evaluated after having received 2 to 6 cycles of chemotherapy, totally 79 cycles. All patients were assessable for toxicity and 20 of 21 patients were assessable for response. Of 20 assessable patients, 6 partial remissions were found （overall response rate, 30.0%）. Stable disease was observed in 8 patients （40.0%） and progressive disease in 6 patients （30.0%）. The median time to progression was 4.5 months. The median overall survival was 8.3 months. In conclusion, capecitabine combined with oxaliplatin is active and well-tolerated in patients with impaired performance status （KPS≤70） and advanced gastric cancer.

关 键 词：胃肿瘤 奥沙利铂 卡培他滨 化疗 

分 类 号：R735.2[医药卫生—肿瘤]